AbbVies risankizumab secures FDA orphan drug status for paediatric Crohns

AbbVie has secured Orphan Drug Designation from the US Food and Drug Administration FDA to risankizumab ABBV066; formerly BI 655066 for the investigational treatment of Crohn's disease in pediatric patients.